

Florian Kurth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4218909/publications.pdf>

Version: 2024-02-01

81
papers

8,316
citations

116194

36
h-index

81351

76
g-index

107
all docs

107
docs citations

107
times ranked

16897
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Severity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-CoV-2: An observational longitudinal study over 12 months. <i>Respiratory Medicine</i> , 2022, 191, 106709. | 1.3 | 63 |
| 2 | Altered fibrin clot structure and dysregulated fibrinolysis contribute to thrombosis risk in severe COVID-19. <i>Blood Advances</i> , 2022, 6, 1074-1087. | 2.5 | 35 |
| 3 | A proteomic survival predictor for COVID-19 patients in intensive care. , 2022, 1, e0000007. | | 28 |
| 4 | mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. <i>Nature Medicine</i> , 2022, 28, 477-480. | 15.2 | 342 |
| 5 | Complement activation induces excessive T cell cytotoxicity in severe COVID-19. <i>Cell</i> , 2022, 185, 493-512.e25. | 13.5 | 122 |
| 6 | Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 445-446. | 4.6 | 28 |
| 7 | Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections. <i>Emerging Infectious Diseases</i> , 2022, 28, 1050-1052. | 2.0 | 11 |
| 8 | Characterization of antimicrobial use and co-infections among hospitalized patients with COVID-19: a prospective observational cohort study. <i>Infection</i> , 2022, 50, 1441-1452. | 2.3 | 10 |
| 9 | <i>In Vitro</i> Screening Identifies TRPV4 and PAR1 as Targets for Endothelial Barrier Stabilization in COVID-19. <i>FASEB Journal</i> , 2022, 36, . | 0.2 | 1 |
| 10 | Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodies. <i>Journal of Clinical Immunology</i> , 2022, 42, 1111-1129. | 2.0 | 17 |
| 11 | A multiplex protein panel assay for severity prediction and outcome prognosis in patients with COVID-19: An observational multi-cohort study. <i>EClinicalMedicine</i> , 2022, 49, 101495. | 3.2 | 17 |
| 12 | Detailed stratified GWAS analysis for severe COVID-19 in four European populations. <i>Human Molecular Genetics</i> , 2022, 31, 3945-3966. | 1.4 | 46 |
| 13 | Hookworm infection in returning travellers and migrants: a 10-year case series at a German center for tropical medicine. <i>Journal of Travel Medicine</i> , 2021, 28, . | 1.4 | 1 |
| 14 | Plasma mediators in patients with severe COVID-19 cause lung endothelial barrier failure. <i>European Respiratory Journal</i> , 2021, 57, 2002384. | 3.1 | 40 |
| 15 | A Dual-Antigen Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in a Low-Transmission Setting. <i>Journal of Infectious Diseases</i> , 2021, 223, 10-14. | 1.9 | 21 |
| 16 | Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. <i>Nature Biotechnology</i> , 2021, 39, 705-716. | 9.4 | 129 |
| 17 | Breakdown in membrane asymmetry regulation leads to monocyte recognition of <i>P. falciparum</i> -infected red blood cells. <i>PLoS Pathogens</i> , 2021, 17, e1009259. | 2.1 | 14 |
| 18 | SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 629185. | 2.2 | 42 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Ultra-fast proteomics with Scanning SWATH. <i>Nature Biotechnology</i> , 2021, 39, 846-854. | 9.4 | 173 |
| 20 | Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study. <i>Infection</i> , 2021, 49, 703-714. | 2.3 | 27 |
| 21 | CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity. <i>Infection</i> , 2021, 49, 757-762. | 2.3 | 47 |
| 22 | In vitro screening identifies TRPV4 as target for endothelial barrier stabilization in COVID-19. <i>FASEB Journal</i> , 2021, 35, . | 0.2 | 1 |
| 23 | Estimating infectiousness throughout SARS-CoV-2 infection course. <i>Science</i> , 2021, 373, . | 6.0 | 389 |
| 24 | Echocardiographic Evaluation of Right Ventricular (RV) Performance over Time in COVID-19-Associated ARDS—A Prospective Observational Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1944. | 1.0 | 0 |
| 25 | Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis. <i>Frontiers in Immunology</i> , 2021, 12, 690698. | 2.2 | 52 |
| 26 | Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1520.e7-1520.e10. | 2.8 | 13 |
| 27 | A serum proteome signature to predict mortality in severe COVID-19 patients. <i>Life Science Alliance</i> , 2021, 4, e202101099. | 1.3 | 62 |
| 28 | Cross-reactive CD4 ⁺ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. <i>Science</i> , 2021, 374, eabh1823. | 6.0 | 221 |
| 29 | A time-resolved proteomic and prognostic map of COVID-19. <i>Cell Systems</i> , 2021, 12, 780-794.e7. | 2.9 | 125 |
| 30 | Outbreak of SARS-CoV-2 B.1.1.7 Lineage after Vaccination in Long-Term Care Facility, Germany, February–March 2021. <i>Emerging Infectious Diseases</i> , 2021, 27, 2169-2173. | 2.0 | 17 |
| 31 | Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1255-1265. | 5.2 | 279 |
| 32 | Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany. <i>Emerging Infectious Diseases</i> , 2021, 27, 2174-2178. | 2.0 | 67 |
| 33 | Early IFN- γ signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. <i>Immunity</i> , 2021, 54, 2650-2669.e14. | 6.6 | 145 |
| 34 | Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01. <i>EClinicalMedicine</i> , 2021, 40, 101099. | 3.2 | 52 |
| 35 | Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers. <i>Lancet Respiratory Medicine</i> , 2021, 9, e104-e105. | 5.2 | 65 |
| 36 | Untimely TGF β 2 responses in COVID-19 limit antiviral functions of NK cells. <i>Nature</i> , 2021, 600, 295-301. | 13.7 | 146 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. <i>Cell</i> , 2021, 184, 6243-6261.e27. | 13.5 | 277 |
| 38 | A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model. <i>Cell</i> , 2020, 183, 1058-1069.e19. | 13.5 | 305 |
| 39 | Evaluation of PEEP and prone positioning in early COVID-19 ARDS. <i>EClinicalMedicine</i> , 2020, 28, 100579. | 3.2 | 49 |
| 40 | Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. <i>Cell</i> , 2020, 182, 1419-1440.e23. | 13.5 | 1,162 |
| 41 | RNAemia Corresponds to Disease Severity and Antibody Response in Hospitalized COVID-19 Patients. <i>Viruses</i> , 2020, 12, 1045. | 1.5 | 53 |
| 42 | Paediatric formulations of artemisinin-based combination therapies for treating uncomplicated malaria in children. <i>The Cochrane Library</i> , 2020, 12, CD009568. | 1.5 | 3 |
| 43 | Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection. <i>Cell Systems</i> , 2020, 11, 11-24.e4. | 2.9 | 439 |
| 44 | Outpatient treatment of imported uncomplicated <i>Plasmodium falciparum</i> malaria: results from a survey among TropNet and GeoSentinel experts for tropical medicine. <i>Journal of Travel Medicine</i> , 2020, 27, . | 1.4 | 1 |
| 45 | Studying the pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19). <i>Infection</i> , 2020, 48, 619-626. | 2.3 | 79 |
| 46 | COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. <i>Nature Biotechnology</i> , 2020, 38, 970-979. | 9.4 | 887 |
| 47 | Prospective observational study on the pharmacokinetic properties of the Iruva ribavirin regimen used in routine clinical practice in patients with Lassa fever in Nigeria. <i>BMJ Open</i> , 2020, 10, e036936. | 0.8 | 4 |
| 48 | Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses. <i>Frontiers in Immunology</i> , 2020, 11, 628971. | 2.2 | 51 |
| 49 | SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. <i>Nature</i> , 2020, 587, 270-274. | 13.7 | 1,115 |
| 50 | Brain magnetic resonance imaging in imported malaria. <i>Malaria Journal</i> , 2019, 18, 74. | 0.8 | 8 |
| 51 | Intravenous Artesunate for Imported Severe Malaria in Children Treated in Four Tertiary Care Centers in Germany. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, e295-e300. | 1.1 | 7 |
| 52 | Determinants of post-malarial anemia in African children treated with parenteral artesunate. <i>Scientific Reports</i> , 2019, 9, 18134. | 1.6 | 6 |
| 53 | Treatment of Severe Malaria. , 2019, , 1-12. | | 0 |
| 54 | Chronic oral ulceration and lip swelling after a long term stay in Guatemala: A diagnostic challenge. <i>Travel Medicine and Infectious Disease</i> , 2018, 23, 103-104. | 1.5 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Recognition of microbial viability via TLR8 drives TFH cell differentiation and vaccine responses. <i>Nature Immunology</i> , 2018, 19, 386-396. | 7.0 | 139 |
| 56 | Chronic airflow obstruction in Tanzania – a cross-sectional study. <i>BMC Pulmonary Medicine</i> , 2018, 18, 11. | 0.8 | 6 |
| 57 | Severe malaria in Europe: an 8-year multi-centre observational study. <i>Malaria Journal</i> , 2017, 16, 57. | 0.8 | 57 |
| 58 | Sentinel surveillance of imported dengue via travellers to Europe 2012 to 2014: TropNet data from the DengueTools Research Initiative. <i>Eurosurveillance</i> , 2017, 22, . | 3.9 | 46 |
| 59 | Schistosomiasis in European Travelers and Migrants: Analysis of 14 Years TropNet Surveillance Data. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 97, 567-574. | 0.6 | 69 |
| 60 | Hemolysis after Oral Artemisinin Combination Therapy for Uncomplicated <i>Plasmodium falciparum</i> Malaria. <i>Emerging Infectious Diseases</i> , 2016, 22, 1381-1386. | 2.0 | 39 |
| 61 | Pyronaridine-artesunate retreatment for malaria. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 136-137. | 4.6 | 0 |
| 62 | Reply to Jaureguiberry et al. <i>Clinical Infectious Diseases</i> , 2016, 62, 271-271. | 2.9 | 2 |
| 63 | Intravenous Artesunate Reduces Parasite Clearance Time, Duration of Intensive Care, and Hospital Treatment in Patients With Severe Malaria in Europe: The TropNet Severe Malaria Study: Figure 1.. <i>Clinical Infectious Diseases</i> , 2015, 61, 1441-1444. | 2.9 | 38 |
| 64 | Continuous Noninvasive Monitoring of Lung Recruitment during High-Frequency Oscillatory Ventilation by Electrical Impedance Measurement: An Animal Study. <i>Neonatology</i> , 2013, 103, 218-223. | 0.9 | 6 |
| 65 | Paediatric Formulations of Artemisinin-Combination Therapies for Treating Uncomplicated Malaria in Children. <i>The Cochrane Library</i> , 2012, , . | 1.5 | 1 |
| 66 | Prospective evaluation of artemether-lumefantrine for the treatment of non-falciparum and mixed-species malaria in Gabon. <i>Malaria Journal</i> , 2012, 11, 120. | 0.8 | 34 |
| 67 | Pyronaridine: a new –old–™ drug on the verge of entering the antimalarial armamentarium. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 393-396. | 2.0 | 6 |
| 68 | In vitro activity of antifungal drugs against <i>Plasmodium falciparum</i> field isolates. <i>Wiener Klinische Wochenschrift</i> , 2011, 123, 26-30. | 1.0 | 6 |
| 69 | Current status of the clinical development and implementation of paediatric artemisinin combination therapies in Sub-Saharan Africa. <i>Wiener Klinische Wochenschrift</i> , 2011, 123, 7-9. | 1.0 | 8 |
| 70 | High prevalence of dhfr triple mutant and correlation with high rates of sulphadoxine-pyrimethamine treatment failures in vivo in Gabonese children. <i>Malaria Journal</i> , 2011, 10, 123. | 0.8 | 35 |
| 71 | The use of paediatric artemisinin combinations in sub-Saharan Africa: a snapshot questionnaire survey of health care personnel. <i>Malaria Journal</i> , 2011, 10, 365. | 0.8 | 5 |
| 72 | Pyronaridine–artesunate combination therapy for the treatment of malaria. <i>Current Opinion in Infectious Diseases</i> , 2011, 24, 564-569. | 1.3 | 19 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Continuous Non-Invasive Monitoring of Tidal Volumes by Measurement of Tidal Impedance in Neonatal Piglets. PLoS ONE, 2011, 6, e21003. | 1.1 | 9 |
| 74 | Efficacy and safety of a new pediatric artesunate-mefloquine drug formulation for the treatment of uncomplicated falciparum malaria in Gabon. Wiener Klinische Wochenschrift, 2010, 122, 173-178. | 1.0 | 22 |
| 75 | Do paediatric drug formulations of artemisinin combination therapies improve the treatment of children with malaria? A systematic review and meta-analysis. Lancet Infectious Diseases, The, 2010, 10, 125-132. | 4.6 | 42 |
| 76 | Adolescence As Risk Factor for Adverse Pregnancy Outcome in Central Africa – A Cross-Sectional Study. PLoS ONE, 2010, 5, e14367. | 1.1 | 80 |
| 77 | No Rebound of Morbidity Following Intermittent Preventive Sulfadoxine–Pyrimethamine Treatment of Malaria in Infants in Gabon. Journal of Infectious Diseases, 2009, 200, 1658-1661. | 1.9 | 15 |
| 78 | Treatment of malaria in Austria: hazardous for patients or physicians?. Wiener Klinische Wochenschrift, 2009, 121, 598-598. | 1.0 | 2 |
| 79 | In vitro activity of pyronaridine against Plasmodium falciparum and comparative evaluation of anti-malarial drug susceptibility assays. Malaria Journal, 2009, 8, 79. | 0.8 | 37 |
| 80 | Fixed-Dose Pyronaridine–Artesunate Combination for Treatment of Uncomplicated Falciparum Malaria in Pediatric Patients in Gabon. Journal of Infectious Diseases, 2008, 198, 911-919. | 1.9 | 91 |
| 81 | Pharmacokinetics of two paediatric artesunate mefloquine drug formulations in the treatment of uncomplicated falciparum malaria in Gabon. Journal of Antimicrobial Chemotherapy, 2007, 60, 1091-1096. | 1.3 | 38 |